$ABOS
Acumen Pharmaceuticals, Inc. Stock $abos

$abos Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000157688524000064 Filed on May 14, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.848M	$5.325M	$4.422M
YoY Change	11.58%	20.42%	37.29%
% of Gross Profit
Research & Development	$19.53M	$12.45M	$8.713M
YoY Change	113.87%	42.88%	45.58%
% of Gross Profit
Depreciation & Amortization	$17.00K	$16.00K	$14.00K
YoY Change	13.33%	14.29%	250.0%
% of Gross Profit
Operating Expenses	$24.38M	$17.77M	$13.14M
YoY Change	80.89%	35.32%	42.68%
Operating Profit	-$24.38M	-$17.77M	-$13.14M
YoY Change	80.89%	35.32%	42.68%
Interest Expense	$3.912M	$1.000M	$1.832M
YoY Change	107.64%	-45.41%	2310.53%
% of Operating Profit
Other Income/Expense, Net	$3.844M	$2.901M	$1.828M
YoY Change	105.78%	58.7%	182700.0%
Pretax Income	-$20.54M	-$14.87M	-$11.31M
YoY Change	76.89%	31.54%	23.86%
Income Tax
% Of Pretax Income
Net Earnings	-$20.54M	-$14.87M	-$11.31M
YoY Change	76.89%	31.54%	23.86%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.34	-$0.25	-$0.28
Diluted Earnings Per Share	-$0.34	-$0.25	-$0.28
COMMON SHARES
Basic Shares Outstanding	60.08M shares	60.08M shares	41.03M shares
Diluted Shares Outstanding	60.08M shares	59.81M shares	41.03M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$260.5M	$252.5M	$140.4M
YoY Change	79.78%	79.84%	-25.74%
Cash & Equivalents	$67.96M	$46.93M	$78.00M
Short-Term Investments	$192.5M	$205.6M	$62.41M
Other Short-Term Assets	$405.0K	$395.0K	$294.0K
YoY Change	94.71%	34.35%	-90.23%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$266.9M	$255.8M	$144.0M
YoY Change	78.49%	77.62%	-25.02%
LONG-TERM ASSETS
Property, Plant & Equipment	$105.0K	$117.0K	$151.0K
YoY Change	-22.79%	-22.52%	-40.08%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$20.91M	$44.11M	$43.42M
YoY Change	-23.44%	1.59%	56.99%
Other Assets	$425.0K	$324.0K	$195.0K
YoY Change	104.33%	66.15%	146.84%
Total Long-Term Assets	$22.00M	$45.14M	$43.83M
YoY Change	-21.06%	2.97%	56.6%
TOTAL ASSETS
Total Short-Term Assets	$266.9M	$255.8M	$144.0M
Total Long-Term Assets	$22.00M	$45.14M	$43.83M
Total Assets	$288.9M	$301.0M	$187.9M
YoY Change	62.86%	60.2%	-14.64%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.211M	$3.079M	$762.0K
YoY Change	107.85%	304.07%	-37.49%
Accrued Expenses	$4.004M	$2.905M	$7.923M
YoY Change	68.66%	-63.33%	202.64%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00
YoY Change
Total Short-Term Liabilities	$15.37M	$8.472M	$8.779M
YoY Change	80.13%	-3.5%	123.04%
LONG-TERM LIABILITIES
Long-Term Debt	$29.38M	$30.21M	$0.00
YoY Change
Other Long-Term Liabilities	$219.0K	$252.0K
YoY Change
Total Long-Term Liabilities	$29.60M	$30.46M	$0.00
YoY Change			-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$15.37M	$8.472M	$8.779M
Total Long-Term Liabilities	$29.60M	$30.46M	$0.00
Total Liabilities	$44.97M	$38.93M	$8.779M
YoY Change	427.09%	343.48%	119.58%
SHAREHOLDERS EQUITY
Retained Earnings	-$258.2M	-$237.7M	-$181.7M
YoY Change	33.57%	30.82%
Common Stock	$6.000K	$6.000K	$4.000K
YoY Change	50.0%	50.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$243.9M	$262.0M	$179.1M
YoY Change
Total Liabilities & Shareholders Equity	$288.9M	$301.0M	$187.9M
YoY Change	62.86%	60.2%	-14.64%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	-$20.54M	-$14.87M	-$11.31M
YoY Change	76.89%	31.54%	23.86%
Depreciation, Depletion And Amortization	$17.00K	$16.00K	$14.00K
YoY Change	13.33%	14.29%	250.0%
Cash From Operating Activities	-$16.55M	-$17.86M	-$10.18M
YoY Change	41.77%	75.52%	22.61%
INVESTING ACTIVITIES
Capital Expenditures	$5.000K	$11.00K	$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities	$37.70M	-$9.192M	-$41.93M
YoY Change	240.78%	-78.08%	723.71%
Cash From Investing Activities	$37.70M	-$9.203M	-$41.93M
YoY Change	240.74%	-78.05%	722.26%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-128.0K	$7.107M	$0.00
YoY Change	-11.72%
NET CHANGE
Cash From Operating Activities	-16.55M	-$17.86M	-$10.18M
Cash From Investing Activities	37.70M	-$9.203M	-$41.93M
Cash From Financing Activities	-128.0K	$7.107M	$0.00
Net Change In Cash	21.03M	-$19.96M	-$52.10M
YoY Change	-2899.73%	-61.7%	288.88%
FREE CASH FLOW
Cash From Operating Activities	-$16.55M	-$17.86M	-$10.18M
Capital Expenditures	$5.000K	$11.00K	$0.00
Free Cash Flow	-$16.55M	-$17.87M	-$10.18M
YoY Change	41.82%	75.63%	22.74%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	us-gaap	Liabilities Liabilities	38933000	usd
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	6000	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	499843000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-237671000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	262034000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	300967000	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12449000	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5325000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4422000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	13135000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-17774000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	53000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	373000	usd
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001576885
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Charlottesville
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	VA
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	22902
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2024Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	60079778	shares
CY2024Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	205582000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3319000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	255831000	usd
CY2024Q1	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	44108000	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	324000	usd
CY2024Q1	us-gaap	Assets Assets	300967000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	3079000	usd
CY2024Q1	abos	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	2367000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2905000	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	17774000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-13135000	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-54000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4000	usd
CY2024Q1	dei	City Area Code CityAreaCode	434
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	297-1000
CY2024Q1	dei	Security12b Title Security12bTitle	Common stock, par value $0.0001 per share
CY2024Q1	dei	Trading Symbol TradingSymbol	ABOS
CY2024Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	46930000	usd
CY2023Q1	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P0Y
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	353000	usd
CY2024Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	234000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	117000	usd
CY2024Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	0	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	121000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	8472000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	252000	usd
CY2024Q1	us-gaap	Long Term Debt LongTermDebt	30209000	usd
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	60079778	shares
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-144000	usd
CY2024Q1	us-gaap	Interest Income Operating InterestIncomeOperating	4005000	usd
CY2023Q1	us-gaap	Interest Income Operating InterestIncomeOperating	1832000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	1000000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	0	usd
CY2024Q1	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	-50000	usd
CY2023Q1	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	0	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2901000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1828000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-14873000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-11307000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-456000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	227000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15329000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11080000	usd
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.25
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.25
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.28
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.28
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	59812000	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	59812000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	41025062	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	41025062	shares
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	266973000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	7938000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-32000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-456000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2484000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-14873000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	262034000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	188775000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	227000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1390000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-11307000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	179085000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-14873000	usd
CY2024Q1	us-gaap	Depreciation Depreciation	16000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	14000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2484000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1390000	usd
CY2024Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1763000	usd
CY2023Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	334000	usd
CY2024Q1	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	-50000	usd
CY2023Q1	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	0	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	28000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	38000	usd
CY2024Q1	us-gaap	Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments	2000	usd
CY2023Q1	us-gaap	Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments	0	usd
CY2024Q1	abos	Other Noncash Expense Interest OtherNoncashExpenseInterest	268000	usd
CY2023Q1	abos	Other Noncash Expense Interest OtherNoncashExpenseInterest	0	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	226000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	899000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-35000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	44000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1700000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-878000	usd
CY2024Q1	abos	Increase Decrease In Accrued Clinical Trial Expenses IncreaseDecreaseInAccruedClinicalTrialExpenses	-2020000	usd
CY2023Q1	abos	Increase Decrease In Accrued Clinical Trial Expenses IncreaseDecreaseInAccruedClinicalTrialExpenses	2486000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-3512000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-603000	usd
CY2024Q1	abos	Increase Decrease In Finance Lease Liability IncreaseDecreaseInFinanceLeaseLiability	-23000	usd
CY2023Q1	abos	Increase Decrease In Finance Lease Liability IncreaseDecreaseInFinanceLeaseLiability	0	usd
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-21000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-38000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17859000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10175000	usd
CY2024Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	45292000	usd
CY2023Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	52131000	usd
CY2024Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	36100000	usd
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	10204000	usd
CY2024Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	11000	usd
CY2023Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	0	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9203000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-41927000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	7938000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2024Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	739000	usd
CY2023Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	0	usd
CY2024Q1	abos	Payments For Deferred Offering Costs PaymentsForDeferredOfferingCosts	60000	usd
CY2023Q1	abos	Payments For Deferred Offering Costs PaymentsForDeferredOfferingCosts	0	usd
CY2024Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	32000	usd
CY2023Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7107000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-19955000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-52102000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	67119000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	130101000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	47164000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	77999000	usd
CY2024Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	756000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2024Q1	abos	Deferred Offering Costs Incurred But Not Yet Paid DeferredOfferingCostsIncurredButNotYetPaid	78000	usd
CY2023Q1	abos	Deferred Offering Costs Incurred But Not Yet Paid DeferredOfferingCostsIncurredButNotYetPaid	0	usd
CY2024Q1	us-gaap	Nature Of Operations NatureOfOperations	DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acumen Pharmaceuticals, Inc. (“Acumen” or the “Company”) was incorporated in 1996 in the state of Delaware. Acumen is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what the Company believes to be a key underlying cause of Alzheimer’s disease (“AD”). Alzheimer’s disease is a progressive neurodegenerative disease of the brain that leads to loss of memory and cognitive functions and ultimately results in death. The Company’s scientific founders pioneered research on soluble amyloid-beta oligomers (“AßOs”), which are globular assemblies of the amyloid-beta (“Aß”) peptide that are distinct from Aß monomers and amyloid plaques. Based on decades of research and supporting evidence, AßOs have gained increasing scientific acceptance as a primary toxin involved in the initiation and propagation of AD pathology. The Company is currently focused on advancing a targeted immunotherapy drug candidate, sabirnetug, in the Phase 2 portion of a Phase 2/3 clinical trial called “ALTITUDE-AD” following Phase 1 results in “early AD” patients (patients with mild cognitive impairment or mild dementia due to Alzheimer’s pathology) that were first reported in July 2023. Sabirnetug is a recombinant humanized immunoglobulin gamma 2 (“IgG2”) monoclonal antibody (“mAb”) that was designed to selectively target AßOs, has demonstrated functional and protective effects in in vitro assays, and has previously demonstrated in vivo safety and pharmacologic activity in multiple animal species, including transgenic mouse models for AD. The Company intends to amend the ALTITUDE-AD clinical protocol in 2024 to change the current Phase 2/3 study to a Phase 2 standalone study. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to the uncertainty of whether its intellectual property will develop into successful commercial products. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Capital Resources </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred operating losses since inception and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. As of March 31, 2024 and December 31, 2023, the Company had an accumulated deficit of $237.7 million and $222.8 million, respectively, and working capital of $247.4 million and $233.6 million, respectively. Management believes that the Company has sufficient cash to continue operating activities for beyond 12 months from issuance of these condensed financial statements. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future capital requirements will depend upon many factors, including the timing and extent of spending on research and development and market acceptance of the Company’s products, if approved for commercial sale. The Company expects that it will need to obtain additional financing to complete clinical trials and launch and commercialize any product candidates for which it receives regulatory approval. Until such time, if ever, as the Company can generate revenue sufficient to achieve profitability, the Company expects to finance its operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. There can be no assurance that any such financing will be available on terms acceptable to the Company, or at all. To the extent that the Company raises additional capital through the sale of equity or convertible debt securities, the ownership interest of its stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting the Company’s ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends. If the Company is unable to maintain sufficient financial resources, its business, financial condition and results of operations will be materially and adversely affected. The Company may be required to delay, limit, reduce or terminate its product discovery and development activities or future commercialization efforts. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company completed a Phase 1 clinical trial of sabirnetug in the second quarter of 2023, which the Company named “INTERCEPT-AD.” This trial enrolled 65 patients with “early AD” and 62 participants received at least one dose of study drug. INTERCEPT-AD was a U.S.-based, multi-center, randomized, double-blind, placebo-controlled clinical trial with overlapping single ascending dose and multiple ascending dose cohorts evaluating patients with early AD. In July 2023, the Company announced topline results from INTERCEPT-AD, which demonstrated that sabirnetug met the primary and secondary objectives of this study in 62 participants with early AD. The Company announced the dosing of the first patient in the ALTITUDE-AD study in May 2024.</span></div>
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-237700000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-222800000	usd
CY2024Q1	abos	Working Capital WorkingCapital	247400000	usd
CY2023Q4	abos	Working Capital WorkingCapital	233600000	usd
CY2023Q2	abos	Number Of Patients Enrolled In Trial NumberOfPatientsEnrolledInTrial	65	patient
CY2023Q2	abos	Number Of Participants Enrolled In Trial With One Dose Of Study Drug Received NumberOfParticipantsEnrolledInTrialWithOneDoseOfStudyDrugReceived	62	participant
CY2023Q3	abos	Number Of Participants Enrolled In Trial With One Dose Of Study Drug Received With Primary And Secondary Objectives Met NumberOfParticipantsEnrolledInTrialWithOneDoseOfStudyDrugReceivedWithPrimaryAndSecondaryObjectivesMet	62	participant
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements, as well as the reported amounts of expenses during the reporting periods. These estimates and assumptions are based on the Company’s historical experience, and on various other factors that management believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual results may differ from these estimates under different assumptions or conditions. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected. The more significant estimates and assumptions by management include, among others: the valuation allowance of deferred tax assets resulting from net operating losses, the valuation of stock options and the valuation of embedded derivatives within the Company’s long-term debt.</span></div>
CY2024Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	46400000	usd
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	66200000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	46930000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	66886000	usd
CY2024Q1	us-gaap	Restricted Cash RestrictedCash	234000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	233000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	47164000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	67119000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	205825000	usd
CY2024Q1	abos	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Current DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent	31000	usd
CY2024Q1	abos	Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Current DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent	274000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	205582000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	44010000	usd
CY2024Q1	abos	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Noncurrent DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent	98000	usd
CY2024Q1	abos	Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Noncurrent DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent	0	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	44108000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	249835000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	129000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	274000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	249690000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	176654000	usd
CY2023Q4	abos	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Current DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent	179000	usd
CY2023Q4	abos	Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Current DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent	197000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	176636000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	62225000	usd
CY2023Q4	abos	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Noncurrent DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent	343000	usd
CY2023Q4	abos	Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Noncurrent DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent	15000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	62553000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	238879000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	522000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	212000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	239189000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	133378000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	180000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	27670000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	94000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	161048000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	274000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	84580000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	158000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	12074000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	54000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	96654000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	212000	usd
CY2024Q1	abos	Debt Securities Available For Sale Noncurrent Term DebtSecuritiesAvailableForSaleNoncurrentTerm	P2Y
CY2024Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2024Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	296085000	usd
CY2024Q1	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	2610000	usd
CY2024Q1	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	2610000	usd
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	305396000	usd
CY2023Q4	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	2560000	usd
CY2023Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	2560000	usd
CY2024Q1	abos	Research And Development Service Agreements Current ResearchAndDevelopmentServiceAgreementsCurrent	2200000	usd
CY2023Q4	abos	Research And Development Service Agreements Current ResearchAndDevelopmentServiceAgreementsCurrent	1680000	usd
CY2024Q1	abos	Prepaid Insurance Current PrepaidInsuranceCurrent	411000	usd
CY2023Q4	abos	Prepaid Insurance Current PrepaidInsuranceCurrent	807000	usd
CY2024Q1	us-gaap	Interest Receivable Current InterestReceivableCurrent	189000	usd
CY2023Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	225000	usd
CY2024Q1	abos	Prepaid Raw Materials Current PrepaidRawMaterialsCurrent	124000	usd
CY2023Q4	abos	Prepaid Raw Materials Current PrepaidRawMaterialsCurrent	98000	usd
CY2024Q1	us-gaap	Other Assets Current OtherAssetsCurrent	395000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	283000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3319000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3093000	usd
CY2024Q1	abos	Research And Development Service Agreements Noncurrent ResearchAndDevelopmentServiceAgreementsNoncurrent	186000	usd
CY2023Q4	abos	Research And Development Service Agreements Noncurrent ResearchAndDevelopmentServiceAgreementsNoncurrent	221000	usd
CY2024Q1	abos	Deferred Offering Costs Noncurrent DeferredOfferingCostsNoncurrent	138000	usd
CY2023Q4	abos	Deferred Offering Costs Noncurrent DeferredOfferingCostsNoncurrent	0	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	324000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	221000	usd
CY2023Q1	abos	Finance Lease Expense FinanceLeaseExpense	0	usd
CY2024Q1	abos	Research And Development Liability Current ResearchAndDevelopmentLiabilityCurrent	1140000	usd
CY2023Q4	abos	Research And Development Liability Current ResearchAndDevelopmentLiabilityCurrent	2186000	usd
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1035000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3692000	usd
CY2024Q1	us-gaap	Interest Payable Current InterestPayableCurrent	249000	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	249000	usd
CY2024Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	481000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	212000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2905000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6339000	usd
CY2022	abos	Leasee Number Of Lease Contracts Entered Into LeaseeNumberOfLeaseContractsEnteredInto	2	lease
CY2024Q1	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	6000	usd
CY2023Q1	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	0	usd
CY2024Q1	abos	Finance Lease Expense FinanceLeaseExpense	6000	usd
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	37000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	40000	usd
CY2024Q1	us-gaap	Variable Lease Cost VariableLeaseCost	1000	usd
CY2023Q1	us-gaap	Variable Lease Cost VariableLeaseCost	0	usd
CY2024Q1	us-gaap	Sublease Income SubleaseIncome	0	usd
CY2023Q1	us-gaap	Sublease Income SubleaseIncome	3000	usd
CY2024Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	38000	usd
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	37000	usd
CY2024Q1	abos	Short Term Lease Rent Expense ShortTermLeaseRentExpense	18000	usd
CY2023Q1	abos	Short Term Lease Rent Expense ShortTermLeaseRentExpense	1000	usd
CY2024Q1	us-gaap	Lease Cost LeaseCost	62000	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	38000	usd
CY2024Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	739000	usd
CY2023Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	0	usd
CY2024Q1	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	23000	usd
CY2023Q1	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	0	usd
CY2024Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	30000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	40000	usd
CY2024Q1	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P3Y6M
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y9M18D
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y4M24D
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.097
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.100
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	113000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	155000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	158000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	426000	usd
CY2024Q1	abos	Common Stock And Preferred Stock Shares Authorized CommonStockAndPreferredStockSharesAuthorized	310000000	shares
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	abos	Common Stock Number Of Voting Rights CommonStockNumberOfVotingRights	1	votingright
CY2022Q3	abos	Sale Of Stock Commission Rate To Sales Agents SaleOfStockCommissionRateToSalesAgents	0.030
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2484000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1390000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7523947	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.01
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2491550	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.87
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10015497	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.98
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	10392000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	4516852	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	3.30
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P7Y
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	8062000	usd
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13158055	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7567393	shares

Files In Submission

Name	View Source	Status
0001576885-24-000064-index-headers.html	Edgar Link	pending
0001576885-24-000064-index.html	Edgar Link	pending
0001576885-24-000064.txt	Edgar Link	pending
0001576885-24-000064-xbrl.zip	Edgar Link	pending
abos-20240331.htm	Edgar Link	pending
abos-20240331.xsd	Edgar Link	pending
abos-20240331x10qxexx311.htm	Edgar Link	pending
abos-20240331x10qxexx312.htm	Edgar Link	pending
abos-20240331x10qxexx321.htm	Edgar Link	pending
abos-20240331x10qxexx322.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
abos-20240331_cal.xml	Edgar Link	unprocessable
abos-20240331_def.xml	Edgar Link	unprocessable
abos-20240331_lab.xml	Edgar Link	unprocessable
abos-20240331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
abos-20240331_htm.xml	Edgar Link	completed
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABOS
Acumen Pharmaceuticals, Inc. Stock $abos

2024 Q2 Form 10-Q Financial Statement

#000157688524000064 Filed on May 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABOS Acumen Pharmaceuticals, Inc. Stock $abos

2024 Q2 Form 10-Q Financial Statement

#000157688524000064 Filed on May 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABOS
Acumen Pharmaceuticals, Inc. Stock $abos